
In a study analyzing data from participants with type 2 diabetes in the ACCORD trial, researchers found that the impact of intensive glycemic control on microvascular outcomes is influenced by long-term variability in HbA1c levels. Lower HbA1c variability in the standard treatment group was linked to a higher risk of microvascular issues, while in the intensive treatment group, higher HbA1c variability increased the risk. Intensive therapy reduced microvascular outcomes for those with lower HbA1c variability but increased the risk for those with high variability. The findings emphasize the importance of dynamic monitoring and timely adjustments to therapeutic strategies in diabetes management.
Like
Save
Share